Department of Gastroenterology, West China Hospital of Sichuan University, No.37 Guo Xue Alley, Chengdu, 610041, Sichuan Province, China.
Department of Day Surgery, West China hospital of Sichuan University, 37 Guoxue Road, Chengdu, 610041, Sichuan, China.
BMC Gastroenterol. 2019 Jun 20;19(1):95. doi: 10.1186/s12876-019-1006-0.
The outcomes of patients with refractory benign esophageal strictures (RBES) are unclear, and the clinical efficacy of dilation versus stent placement is lacking. Our objective was to explore the role of endoscopic dilation and stents placement in the management of RBES.
RBES patients treated with dilation and stents in our hospital between January 2009 and December 2017 were included in this study. The primary outcomes were to assess clinical effectiveness and adverse events. The secondary outcome was to identify factors that predicted the dysphagia-free period.
Among 75 RBES patients (54 male; median age 59 years), 39 (52%), 20 (26.7%), 3 (4%), 10 (13.3%), and 3 (4%), were postsurgical, post-ESD, achalasia of cardia, caustic and mixed etiology, respectively. The median number of endoscopic therapy was 5 times (range 3, 21). Endoscopic therapy was successful in 46 patients (61.3%). Patients treated with dilation showed a higher success rate (70.9%, 39/55) than that treated with stents (35%, 7/20). Fifteen patients died during follow-up. Nineteen patients had adverse events after endoscopic therapy. In total, the mean dysphagia-free period was 3.4 months (95% CI, 2.5-4.3). The patients treated with dilation demonstrated a dysphagia-free period of 3.7 months (95% CI, 2.7-5), while patients treated with stents displayed a dysphagia-free period of 2.3 months (95% CI, 1.5-3). The dysphagia-free period had a linear growth trend over time, with an increase of 12 days per endoscopic therapy.
The dysphagia-free period increased by 12 days per endoscopic therapy, so the endoscopic therapy tended to be effective in patients with RBES by increasing the dysphagia-free period. However, compared to dilation therapy, stent therapy was not effective in increasing the dysphasia-free period and reducing the times and frequency of dilation. In addition, univariate and multivariate analyses also indicated that etiology may predict the endoscopic therapy outcome.
This study was retrospectively registered and approved by the Ethics Committee of West China Hospital of Sichuan University (IRB number: ChiCTR1800016321 ).
难治性良性食管狭窄(RBES)患者的预后尚不清楚,扩张与支架置入的临床疗效也缺乏相关研究。本研究旨在探讨内镜下扩张和支架置入在 RBES 管理中的作用。
纳入 2009 年 1 月至 2017 年 12 月在我院接受扩张和支架置入治疗的 RBES 患者。主要结局评估临床疗效和不良事件。次要结局为确定预测吞咽困难无复发期的因素。
75 例 RBES 患者(男 54 例,中位年龄 59 岁)中,分别有 39 例(52%)、20 例(26.7%)、3 例(4%)、10 例(13.3%)和 3 例(4%)为术后、内镜黏膜下剥离术(ESD)后、贲门失弛缓症、腐蚀性和混合病因。内镜治疗中位次数为 5 次(范围 3-21 次)。46 例(61.3%)患者治疗成功。扩张治疗组的成功率(70.9%,39/55)高于支架治疗组(35%,7/20)。随访期间 15 例患者死亡。19 例患者内镜治疗后出现不良事件。总体而言,平均无吞咽困难期为 3.4 个月(95%CI,2.5-4.3)。扩张治疗组无吞咽困难期为 3.7 个月(95%CI,2.7-5),支架治疗组为 2.3 个月(95%CI,1.5-3)。无吞咽困难期随时间呈线性增长趋势,每次内镜治疗增加 12 天。
无吞咽困难期每增加 12 天,提示内镜治疗可能通过增加无吞咽困难期来提高 RBES 患者的疗效。但与扩张治疗相比,支架治疗在增加无吞咽困难期、减少扩张次数和频率方面效果不佳。此外,单因素和多因素分析也表明,病因可能预测内镜治疗结果。
本研究为回顾性研究,经四川大学华西医院伦理委员会批准(注册号:ChiCTR1800016321)。